Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Astellas, the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended September 30, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com.  The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Your Contact at Bayer:Doreen Schroeder, Tel. +49 30 468-11399E-Mail: doreen.schroeder@bayer.com Your Investor Relations Contact at Regeneron:Michael Aberman, M.D. Tel. +1 (914) 345-7799E-Mail: michael.aberma
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today ... Logo - ... "Our new corporate identity signifies our transformation into ... first predictive analytics platform for patent claim validity." ... launch of the proprietary AIA Shield™ platform, the Company commenced ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... 2011 Cell Biosciences, Inc. today announced that it ... approximately U.S. $9 million in cash. ... (MFI), an analytical technique used to detect particles and ... protein aggregation expressed by the FDA and other regulatory ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Increase Focus on Super Generics and ... http://www.reportlinker.com/p0491876/Generic-Growth-Strategies---Manufacturers-to-Increase-Focus-on-Super-Generics-and-Biosimilars-to-Drive-Revenues.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Vitamin_and_Supplement ...
Cached Medicine Technology:Cell Biosciences Acquires Brightwell Technologies 2Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 2Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 3Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 4Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 5Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 6Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 7
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... briefs due to insufficient scrotal support and protection against dribbled urine and sweat. ... inventor from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ProDrop Particles ... . Each preset contains 15 seconds of unique footage that users can shrink and ... fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, and ...
(Date:8/28/2015)... ... 2015 , ... Rio Salado College joined nine educational institutions in ... of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by ... Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed to bring ...
(Date:8/28/2015)... ... August 28, 2015 , ... An article published August ... Paul LaRocco has gone through to open a pizzeria in Westchester. Mr. LaRocco was ... to take several months, but the current process, having already gone on for over ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the City, ... added yet another accolade to its cadre of widespread support—an official letter of support ... help of the medical community and the University of Illinois at Chicago’s Department of ...
Breaking Medicine News(10 mins):Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3
... lawsuit,(Case #08CV5874) against long-term skilled nursing corporation Extendicare,and its ... by city at end of,release] was just filed in ... Laura Bernstein vs. Extendicare Health Services, Inc. and Extendicare,Homes, ... residents who lived in,a Minnesota Extendicare facility from Oct. ...
... Air Methods Corporation,(Nasdaq: AIRM ) announces the following Webcast:, ... November 6, 2008 @ 4:15 p.m. ET, ... Live over the Internet -- Simply log on to the ... address above., Contact: Christine Clarke of Air Methods ...
... Eating Disorders, PHOENIX, Oct. 30 As the ... worried about treatment and not,seeking the help they desperately ... an eating disorder can be very,serious because they can ... director of psychological services at Remuda Ranch,Programs for Eating ...
... Jeffrey A. Niezgoda and Dr. Peter J. Sordi provide updates on a wide ... - John St. John, Ph.D. gives perspectives on design and features of ... ... ULU ) --,Clinical updates and new case studies on the application of Altrazeal(TM) ...
... Personal Genetics Company Singled Out for Pioneering Retail Genomics , ... ... Magazine announced today that the Personal Genome Service™ from 23andMe ... was chosen as the year,s most significant invention for its exceptional ...
... more than $6 million dollars have been awarded to ... Institute for Medical Research (WAIMR), in support of a ... WAIMR scientists have shared 10 research grants from the ... Research Council (ARC) announced last week placing the Institute,s ...
Cached Medicine News:Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 2Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 3Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 4Health News:10 Minnesota Nursing Homes Named in Class Action Lawsuit Against Extendicare 5Health News:Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need 2Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 2Health News:ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care 3Health News:TIME Magazine Names 23andMe's Personal Genome Service 2008 Invention of the Year 2Health News:TIME Magazine Names 23andMe's Personal Genome Service 2008 Invention of the Year 3Health News:TIME Magazine Names 23andMe's Personal Genome Service 2008 Invention of the Year 4Health News:National grants further WA Medical Research 2
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: